Genmab’s sBLA for Arzerra granted Priority Review
FDA has awarded its Priority Review designation to the Genmab-developed cancer drug Arzerra as a maintenance therapy for relapsed CLL with a decision expected by January 21.
BY MARTIN HAVTORN PETERSEN
The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for ofatumumab (Arzerra) as maintenance therapy of patients with relapsed chronic lymphocytic leukemia (CLL), Denmark’s Genmab says in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Gilead to use Genmab drug in cancer combo
For abonnenter
Novartis hails Genmab drug
For abonnenter
Market situation intensifies for Arzerra
For abonnenter
